RBC Life Sciences receives U.S. patent for Neurobright supplement

Published on January 31, 2013 at 1:30 AM · No Comments

RBC Life Sciences, Inc. (OTCQB: RBCL) (the "Company"), has been granted US Patent 8357422, which protects its unique dietary supplement formulation that nutritionally supports cognitive function, learning and remembering.  The Company markets this supplement under the name "Neurobright®." The grant of this patent evidences the Company's continued commitment to bring effective science-based dietary supplements to the market.

"The basis for the patent was an 18-month controlled animal study conducted by Dr. Tres Thompson of the School of Behavioral and Brain Sciences at the University of Texas at Dallas," said Clinton Howard , CEO. "The study showed that Neurobright increased both cognitive function and psychomotor abilities in animals."

Dr. Thompson presented the report on this study at the 2008 annual conference of the Society for Neuroscience. The report stated, "Neurobright enabled aging animals to have memory and learning function like younger animals." In describing his observations from the study, Dr. Thompson said, "Some prescription drugs will improve cognitive function, but not once in my 25-year tenure, have test subjects improved so dramatically from a safe and natural product."

In addition to improved cognitive function, the animals that received Neurobright lived longer than the control animals that were not given Neurobright.

SOURCE RBC Life Sciences, Inc.

Posted in: Medical Science News | Medical Patent News | Pharmaceutical News

Tags: , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post